Study Summary: This study is for kids, teens, and young adults with a specific type of blood cancer called B-cell Acute Lymphoblastic Leukemia (B-ALL). The study will test a combination of drugs: blinatumomab, dasatinib, or imatinib, with standard chemotherapy. Blinatumomab helps the immune system fight cancer, while dasatinib and imatinib stop cancer cells from growing. The study aims to see if this combination is better than current treatments.
- Length of Study: Treatment can last up to 2 years with regular check-ups.
- Visits Needed: Regular hospital visits are required for treatments and tests.
- Potential Risks: Includes infections, bleeding, and reactions to drugs.
Participants must be younger than 25 and have specific types of leukemia. They need to have started some initial therapy and meet health criteria. Pregnant individuals and those with certain health conditions cannot join. Participants must agree to use contraception during the study.
This study involves a lot of hospital time and medical tests but could improve treatment for this type of leukemia.